| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 9,090 | 49,770 | 14,720 | 46,550 | 54,130 |
| Sales Growth | -81.74% | +238.11% | -68.38% | -14.00% | +773.06% |
| Net Income | -156,430 | -102,180 | -170,220 | -161,990 | -129,720 |
| Net Income Growth | -53.09% | +39.97% | -5.08% | -24.88% | -51.42% |
Zealand Pharma A/S (ZLDPF)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
84.5000 -14.4100 (-14.57%) 03/14/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 84.5000 unch (unch) 14:44 ET
for Fri, Mar 14th, 2025
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.
Fiscal Year End Date: 12/31